AIRS vs. CDNA, AGL, PNTG, AVAH, FLGT, INNV, PSNL, CSTL, CELC, and SBC
Should you be buying AirSculpt Technologies stock or one of its competitors? The main competitors of AirSculpt Technologies include CareDx (CDNA), Agilon Health (AGL), The Pennant Group (PNTG), Aveanna Healthcare (AVAH), Fulgent Genetics (FLGT), InnovAge (INNV), Personalis (PSNL), Castle Biosciences (CSTL), Celcuity (CELC), and SBC Medical Group (SBC). These companies are all part of the "healthcare" industry.
AirSculpt Technologies vs. Its Competitors
CareDx (NASDAQ:CDNA) and AirSculpt Technologies (NASDAQ:AIRS) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, institutional ownership, valuation, profitability, media sentiment, analyst recommendations, earnings and dividends.
CareDx presently has a consensus price target of $29.33, suggesting a potential upside of 126.25%. AirSculpt Technologies has a consensus price target of $3.75, suggesting a potential downside of 33.76%. Given CareDx's stronger consensus rating and higher probable upside, research analysts plainly believe CareDx is more favorable than AirSculpt Technologies.
CareDx has higher revenue and earnings than AirSculpt Technologies. AirSculpt Technologies is trading at a lower price-to-earnings ratio than CareDx, indicating that it is currently the more affordable of the two stocks.
In the previous week, CareDx had 10 more articles in the media than AirSculpt Technologies. MarketBeat recorded 10 mentions for CareDx and 0 mentions for AirSculpt Technologies. CareDx's average media sentiment score of 0.19 beat AirSculpt Technologies' score of 0.00 indicating that CareDx is being referred to more favorably in the media.
CareDx has a net margin of 19.79% compared to AirSculpt Technologies' net margin of -9.95%. CareDx's return on equity of 21.16% beat AirSculpt Technologies' return on equity.
CareDx has a beta of 2.19, indicating that its stock price is 119% more volatile than the S&P 500. Comparatively, AirSculpt Technologies has a beta of 2.46, indicating that its stock price is 146% more volatile than the S&P 500.
91.5% of AirSculpt Technologies shares are owned by institutional investors. 4.4% of CareDx shares are owned by insiders. Comparatively, 76.6% of AirSculpt Technologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Summary
CareDx beats AirSculpt Technologies on 13 of the 16 factors compared between the two stocks.
Get AirSculpt Technologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for AIRS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding AIRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
AirSculpt Technologies Competitors List
Related Companies and Tools
This page (NASDAQ:AIRS) was last updated on 7/21/2025 by MarketBeat.com Staff
Free AIRS Stock Alerts